Response by O’Donoghue et al to Letter Regarding Article, “Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease”

HomeCirculationVol. 147, No. 16Response by O’Donoghue et al to Letter Regarding Article, “Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease” No AccessResearch ArticleRequest AccessFull TextAboutView Full TextView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toNo AccessResearch ArticleRequest AccessFull TextResponse by O’Donoghue et al to Letter Regarding Article, “Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease” Michelle L. O’Donoghue, Robert P. Giugliano and Marc S. Sabatine Michelle L. O’DonoghueMichelle L. O’Donoghue https://orcid.org/0000-0002-8663-0067 TIMI (Thrombolysis in Myocardial Infarction) Study Group, Division of Cardiovascular Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA. Search for more papers by this author , Robert P. GiuglianoRobert P. Giugliano https://orcid.org/0000-0003-4110-7675 TIMI (Thrombolysis in Myocardial Infarction) Study Group, Division of Cardiovascular Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA. Search for more papers by this author and Marc S. SabatineMarc S. Sabatine https://orcid.org/0000-0002-0691-3359 TIMI (Thrombolysis in Myocardial Infarction) Study Group, Division of Cardiovascular Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA. Search for more papers by this author Originally published17 Apr 2023https://doi.org/10.1161/CIRCULATIONAHA.123.064048Circulation. 2023;147:1258–1259"Response by O’Donoghue et al to Letter Regarding Article, “Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease”." Circulation, 147(16), pp. 1258–1259FootnotesCirculation is available at www.ahajournals.org/journal/circReferences1. O’Donoghue ML, Giugliano RP, Wiviott SD, Atar D, Keech A, Kuder JF, Im K, Murphy SA, Flores-Arredondo JH, Lopez JAG, et al. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease.Circulation. 2022; 146:1109–1119. doi: 10.1161/CIRCULATIONAHA.122.061620LinkGoogle Scholar2. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, et al; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease.N Engl J Med. 2017; 376:1713–1722. doi: 10.1056/NEJMoa1615664CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetails April 18, 2023Vol 147, Issue 16 Advertisement Article InformationMetrics © 2023 American Heart Association, Inc.https://doi.org/10.1161/CIRCULATIONAHA.123.064048PMID: 37068132 Originally publishedApril 17, 2023 PDF download Advertisement SubjectsBlood Pressure